In the biotech sector, we have seen a notable decline over the past months in the value of
Bayer stocks. There have been significant legal issues resulting in the need to possibly pull the
weedkiller from the market altogether. A
slump in stock value came in the wake of a
$2 billion Roundup case verdict. In response, Bayer petitioned the U.S. Supreme Court to review the case. Amidst these setbacks, the company is planning
new launches intended to offset the Xarelto patent expiry. Furthermore, Bayer shares hit a
two-decade low, resulting in market scrutiny, despite assertions from some quarters that it's a
buy again situation. The company seeks investor approval for a 35% cash call to prepare for litigation. However, Bayer is also facing
weak Q3 performance and a guidance cut, contributing to the continuous
share drop. While there has been some recovery, the company’s
outlook has been cautiously described as ‘
not pretty’, with various members of its board making significant
share purchases.
BAYER Stocks News Analytics from Tue, 06 Aug 2024 07:00:00 GMT to Fri, 25 Apr 2025 16:02:43 GMT -
Rating -8
- Innovation -2
- Information 2
- Rumor -4
